Member Info for Icecool

Not a quiet week for me! Off to Birmingham tomorrow to get absolutely hammered at Marie Vaunt. Let’s go! 🤣🤣🙌

Ah ok, that makes sense.

I wouldn’t give it much thought. Rich certainly isn’t one of the board’s main contributors when it comes to research or company information.

He’s only really appeared recently to take a consistently negative stance on Avacta. If I had to guess, I’d say it’s just a generic second trading account trying to appear more diplomatic and reinforce different agendas (Pathetic TBH everyone should only use 1 account, grow a pair), while still pushing a bearish narrative, not a known poster like Touk for example.

The third person post was amusing though. 🤣🤣.

BV, I thought you were more perceptive than that. 🤣

Rich complaining about Rich getting reported… from the Rich account… in the third person.

Reads like someone forgot to log into the other account first. 😭🤦‍♂️

“Guys, stop mass reporting RichMackintyre, I dont agree with everything he posts but I welcome the debate.”

What a donkey you forgot to log into your second account!! Jesus 🤣🤣🤣🤦‍♂️

That’s the AIM mentality I have been seeing over X as well, lack of patience and investment fatigue, You’re obsessing over short term dilution and completely missing the bigger picture.

If AVA6103 validates the platform, any additional dilution becomes largely irrelevant compared with the value created with negotiation leverage.

I’d much rather own a slightly smaller slice of a vastly more valuable company than 100% of something worth far less by doing a deal early.

Shareholders need to realise, Avacta holds all the cards and can raise anytime to increase leverage with additional data. They still own 100% of the platform. That’s way more valuable than some short term pain regarding potential SP and dilution.

Will be extremely interesting, hopefully we get a boring update Guidance on target, H2 going as expected.

If that happens the Shorts are screwed, all the negativity was on so called cash issues generated and amplified by the press that hasn’t materialised.

H2 is expected to be much better. 💯👍

It’s the AVA6103 data they’re really waiting for.

If those data are positive, as many of us expect, and made public, Avacta moves from being viewed as a company with a single promising drug to a validated platform with two clinical assets.

In my opinion, successful AVA6103 data would significantly increase the value of not only the platform but AVA6000 as well, imo it would increase the negotiation leverage 10 fold. 👍

Ffs stop entertaining the mentally ill he is trolling the BB. Just filter ignore and move on.

Please stop entertaining the mentally ill ffs 👍

Stick with company guidance as we move into H2.

Probably!! 🤣🤣🤣

Maybe I should have given Laura G a call. 🤣🤣

All joking aside, you win some, you lose some. I’ve had several winners recently, including Stateside with NVTS and Tempus, plus Saga.

Avacta, though, continues to look extremely promising from a fundamental perspective.

My advice, Do your own research, have patience and filter out the bottom-feeding traders who obsess over every daily moves and flip/flop doesn’t take a rocket scientist to figure out who I’m referring too…. It’s LDA🙄🙄🤣. 👍

TBF I did lose 174k on TRX so I can’t really say anything… 🤣🤣🙄

“I lost £17,400 since COVID chasing biotech penny stocks that promised the moon. I'd buy at the peak of hype, then hold all the way down until they crashed 90%. My portfolio was a graveyard of broken dreams.”

Sounds like Windy portfolio tbh… 🤣🤣👏

Yes, we are in Q3. 🙄🙄

Well done. 🤣👏

Q3 also runs for three months, which was the fairly obvious point.

The company said further data are expected in Q3, not that Gemstar gets a personal update the minute the quarter starts. 🤦‍♂️🤦‍♂️🤦‍♂️

Are you really that dense? 🤦‍♂️

Be patient… or write a strongly worded social media post demanding an update like LDA. 🤣

The company has already said more data are expected in Q3. It really isn’t that difficult to understand. 👍

Jesus 🤣🤣👇👇

Further data updates expected in Q3 2026

Not difficult to understand. 😂

Can you not read latest RNS!! 👇👇

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference

Responses observed in patients with very low FAP expression with persistence of FAP expression observed despite tumor response

Further data updates expected in Q3 2026

Taken from RNS, good luck getting a legal case from the below!!! 👇👇

UK Competition and Markets Authority consults on proposed voluntary commitmentsin housebuilding investigation

Vistry Group plc ("Vistry") notes the UK Competition and Markets Authority's ("CMA") announcement today[1] that it is inviting views on voluntary commitments offered by Vistry and six other UK housebuilders[2] as part of the CMA's ongoing investigation in the housebuilding sector.

Vistry has engaged proactively with the CMA throughout its investigation, including by voluntarily offering binding commitments ("Voluntary Commitments") in response to the potential concerns investigated by the CMA, and with a view to resolving the investigation expeditiously.

The Voluntary Commitments include a commitment by Vistry and the six other UK housebuilders to contribute £100 million in aggregate to His Majesty's Government which shall be disbursed to government programmes which fund and support the construction of affordable homes in England, Scotland, Wales and Northern Ireland. Vistry will contribute £12.8 million as part of this commitment.

Vistry's offer of the Voluntary Commitments does not constitute an admission of any wrongdoing by it nor may it be construed as implying that Vistry agrees with any concerns expressed by the CMA, including those set out in the Notice of Intention to Accept Commitments of 9 July 2025[3].

Vistry welcomes the CMA's consultation on the Voluntary Commitments and will continue to work constructively with the CMA throughout the process.

Cut and paste from my previous message’s 👇👇

The raise appears to have been structured on the assumption that the bondholder could accelerate the deferred repayments after 30 June, with the intention of settling them in cash rather than shares, thereby reducing potential dilution.

Perhaps part of the market uncertainty has simply been around whether those repayments would ultimately be made in cash or equity.

I would note that the TNBC data was linked to the date of acceleration, not the acceleration itself. The latest RNS suggests they will announce maturing data later in the year that’s likely a good thing. 💯👍🤔

Did I not go over the bond last week!! 🤣🤦‍♂️